CVS Group plc (LON:CVSG) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• CVS Group has a “Moderate Buy” consensus rating from six analysts, with four buys and two holds. The average 12-month price target is GBX 1,666.67, above the reported opening price of GBX 1,217.04.
• Recent analyst targets range from GBX 1,400 from Jefferies and Shore Capital, both with hold ratings, to GBX 2,000 from Berenberg, which reiterated its buy rating.
• Company insiders purchased 3,860 shares worth approximately £4.96 million over the past quarter, while CVS Group shares were reported down 6.5%; the company posted quarterly EPS of GBX 85.60.

Shares of CVS Group plc (LON:CVSG - Get Free Report) have earned an average rating of "Moderate Buy" from the six ratings firms that are currently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is GBX 1,666.67.

Several analysts recently weighed in on the company. Jefferies Financial Group increased their price target on CVS Group from GBX 1,350 to GBX 1,400 and gave the company a "hold" rating in a report on Friday, July 31st. Berenberg Bank reaffirmed a "buy" rating and set a GBX 2,000 price target on shares of CVS Group in a research note on Thursday. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a GBX 1,700 price objective on shares of CVS Group in a research report on Monday, July 27th. Finally, Shore Capital Group reaffirmed a "hold" rating and set a GBX 1,400 target price on shares of CVS Group in a research note on Thursday.

Insiders Place Their Bets

In related news, insider David Wilton purchased 1,500 shares of CVS Group stock in a transaction that occurred on Tuesday, August 4th. The shares were bought at an average price of GBX 1,276 per share, with a total value of £19,140. Also, insider Robin Alfonso acquired 768 shares of the stock in a transaction on Thursday, August 6th. The stock was bought at an average cost of GBX 1,294 per share, with a total value of £9,937.92. Insiders have acquired a total of 3,860 shares of company stock worth $4,956,696 over the last quarter. Company insiders own 1.48% of the company's stock.

CVS Group Trading Down 6.5%

Shares of CVSG opened at GBX 1,217.04 on Thursday. The stock has a market capitalization of £827.22 million, a PE ratio of 17.66, a P/E/G ratio of 1.77 and a beta of 1.07. The company's fifty day moving average is GBX 1,289.88 and its 200 day moving average is GBX 1,230. The company has a debt-to-equity ratio of 92.34, a quick ratio of 0.90 and a current ratio of 1.07. CVS Group has a fifty-two week low of GBX 1,062 and a fifty-two week high of GBX 1,648.

CVS Group (LON:CVSG - Get Free Report) last issued its quarterly earnings data on Thursday, September 24th. The company reported GBX 85.60 EPS for the quarter. CVS Group had a net margin of 2.31% and a return on equity of 5.35%. Sell-side analysts expect that CVS Group will post 93.9393939 earnings per share for the current fiscal year.

About CVS Group

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy. The Group operates from over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct"). The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.